Antipsychotic Treatments for the Elderly: Efficacy and Safety of Aripiprazole

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2010 Apr 3

PMID 20361061

Citations 11

Authors

Izchak Kohen

Paula E Lester

Sum Lam

Affiliations

Soon will be listed here.

Abstract

Delusions, hallucinations and other psychotic symptoms can accompany a number of conditions in late life. As such, elderly patients are commonly prescribed antipsychotic medications for the treatment of psychosis in both acute and chronic conditions. Those conditions include schizophrenia, bipolar disorder, depression and dementia. Elderly patients are at an increased risk of adverse events from antipsychotic medications because of age-related pharmacodynamic and pharmacokinetic changes as well as polypharmacy. Drug selection should be individualized to the patient's previous history of antipsychotic use, current medical conditions, potential drug interactions, and potential side effects of the antipsychotic. Specifically, metabolic side effects should be closely monitored in this population. This paper provides a review of aripiprazole, a newer second generation antipsychotic agent, for its use in a variety of psychiatric disorders in the elderly including schizophrenia, bipolar disorder, dementia, Parkinson's disease and depression. We will review the pharmacokinetics and pharmacodynamics of aripiprazole as well as dosing, diagnostic indications, efficacy studies, and tolerability including its metabolic profile. We will also detail patient focused perspectives including quality of life, patient satisfaction and adherence.

Citing Articles

Effectiveness of pharmacological and non-pharmacological interventions for treatment-resistant depression in older patients: a systematic review and meta-analysis.

Larsen A, Teobaldi G, Espinoza Jeraldo R, Falkai P, Cooper C BMJ Ment Health. 2025; 28(1).

PMID: 40032553 PMC: 11877238. DOI: 10.1136/bmjment-2024-301324.

Acute Angle-closure Glaucoma Associated with Aripiprazole: A Case Report.

Vishwanath R, Soman S, Nagaraj A, Kamath A, Penmetsa T Indian J Psychol Med. 2024; 46(3):273-274.

PMID: 38699760 PMC: 11062306. DOI: 10.1177/02537176231199210.

Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies.

Kwon D, Kwatra M, Wang J, Ko H Cells. 2022; 11(23).

PMID: 36496996 PMC: 9736114. DOI: 10.3390/cells11233736.

Sex Differences in Demographic and Pharmacological Factors in Alzheimer Patients With Dementia and Cognitive Impairments.

Coker-Ayo O, Nathaniel S, Poupore N, Bailey-Taylor M, Roley L, Goodwin R Front Behav Neurosci. 2022; 16:828782.

PMID: 35431827 PMC: 9012112. DOI: 10.3389/fnbeh.2022.828782.

Therapeutic Effects of Aripiprazole in the 5xFAD Alzheimer's Disease Mouse Model.

Jeong Y, Son Y, Park H, Oh S, Choi J, Ko Y Int J Mol Sci. 2021; 22(17).

PMID: 34502282 PMC: 8431331. DOI: 10.3390/ijms22179374.

References

Kern R, Green M, Cornblatt B, Randall Owen J, McQuade R, Carson W . The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl). 2006; 187(3):312-20. DOI: 10.1007/s00213-006-0428-x. View

Gildengers A, Mulsant B, Begley A, McShea M, Stack J, Miller M . A pilot study of standardized treatment in geriatric bipolar disorder. Am J Geriatr Psychiatry. 2005; 13(4):319-23. DOI: 10.1176/appi.ajgp.13.4.319. View

Heaton R, Gladsjo J, Palmer B, Kuck J, Marcotte T, Jeste D . Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry. 2001; 58(1):24-32. DOI: 10.1001/archpsyc.58.1.24. View

Hamilton M . A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62. PMC: 495331. DOI: 10.1136/jnnp.23.1.56. View

Boulton D, Kollia G, Mallikaarjun S, Komoroski B, Sharma A, Kovalick L . Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Clin Pharmacokinet. 2008; 47(7):475-85. DOI: 10.2165/00003088-200847070-00004. View

Jeste D, Finkel S . Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000; 8(1):29-34. DOI: 10.1097/00019442-200002000-00004. View

Casey D, Carson W, Saha A, Liebeskind A, Ali M, Jody D . Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003; 166(4):391-9. DOI: 10.1007/s00213-002-1344-3. View

Madhusoodanan S, Shah P, Brenner R, Gupta S . Pharmacological treatment of the psychosis of Alzheimer's disease: what is the best approach?. CNS Drugs. 2007; 21(2):101-15. DOI: 10.2165/00023210-200721020-00002. View

Friedman J, Berman R, Goetz C, Factor S, Ondo W, Wojcieszek J . Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006; 21(12):2078-81. DOI: 10.1002/mds.21091. View

10.

Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W . Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006; 20(4):536-46. DOI: 10.1177/0269881106059693. View

11.

Papakostas G, Shelton R, Smith J, Fava M . Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007; 68(6):826-31. DOI: 10.4088/jcp.v68n0602. View

12.

Palmer B, McClure F, Jeste D . Schizophrenia in late life: findings challenge traditional concepts. Harv Rev Psychiatry. 2001; 9(2):51-8. DOI: 10.1080/10673220127883. View

13.

DeLeon A, Patel N, Crismon M . Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004; 26(5):649-66. DOI: 10.1016/s0149-2918(04)90066-5. View

14.

McEvoy J, Daniel D, Carson Jr W, McQuade R, Marcus R . A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res. 2007; 41(11):895-905. DOI: 10.1016/j.jpsychires.2007.05.002. View

15.

Solomon D, Portner T, Bass G, GOURLEY D, Gourley G, Holt J . Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc (Wash). 1998; 38(5):574-85. DOI: 10.1016/s1086-5802(16)30371-0. View

16.

Paulsen J, Salmon D, Thal L, Romero R, Galasko D, Hofstetter C . Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology. 2000; 54(10):1965-71. DOI: 10.1212/wnl.54.10.1965. View

17.

De Deyn P, Jeste D, Swanink R, Kostic D, Breder C, Carson W . Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin Psychopharmacol. 2005; 25(5):463-7. DOI: 10.1097/01.jcp.0000178415.22309.8f. View

18.

Cutler A, Marcus R, Hardy S, ODonnell A, Carson W, McQuade R . The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr. 2006; 11(9):691-702. DOI: 10.1017/s1092852900014784. View

19.

Ostling S, Skoog I . Psychotic symptoms and paranoid ideation in a nondemented population-based sample of the very old. Arch Gen Psychiatry. 2002; 59(1):53-9. DOI: 10.1001/archpsyc.59.1.53. View

20.

Rutherford B, Sneed J, Miyazaki M, Eisenstadt R, Devanand D, Sackeim H . An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. Int J Geriatr Psychiatry. 2007; 22(10):986-91. DOI: 10.1002/gps.1775. View